DiaSorin SpA (DIAS)

Currency in EUR
82.38
-0.72(-0.87%)
Real-time Data·
Advertisement
DIAS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
82.3483.00
52 wk Range
52.3485.82
Key Statistics
Prev. Close
83.1
Open
82.6
Day's Range
82.34-83
52 wk Range
52.34-85.82
Volume
25.71K
Average Volume (3m)
168.32K
1-Year Change
39.9592%
Book Value / Share
29.63
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DIAS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
79.63
Downside
-3.34%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 7 consecutive years

DiaSorin SpA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

6 Buy
3 Hold
5 Sell
Ratings:
14 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 79.63
(-3.34% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Deutsche Bank
Sell70.00-15.03%60.00Maintain16/11/2026
RBC Capital
Buy95.00+15.32%80.00Maintain23/10/2026
Morgan Stanley
Hold78.00-5.32%71.00Maintain09/10/2026
Barclays
Sell70.00-15.03%60.00Maintain08/09/2026
Kepler Cheuvreux
Hold76.00-7.74%-Downgrade02/09/2026

DiaSorin SpA Earnings Call Summary for Q3/2026

  • DiaSorin Q3 revenue rose 8% at constant rates to €308M; adjusted EBITDA margin improved to 34%, driving shares up 3.36% to near 52-week high.
  • Molecular diagnostics surged 36% in multiplexing; NES point-of-care platform gaining U.S. traction through McKesson distribution partnership.
  • Company reaffirmed 2026 guidance: 5-6% revenue growth and 32-33% adjusted EBITDA margin, assuming normal respiratory season with PLEX contribution.
  • China reagent sales fell 12% in Q3 amid procurement pressure; PAMA reimbursement changes pose potential 2027 headwind for U.S. diagnostics.
  • Net debt declined €60M to €782M; free cash flow reached €127M nine-month despite inventory buildup for NES platform launch.
Last Updated: 12/11/2026, 16:20
Read Full Transcript

Earnings

Latest Release
12/11/2026
EPS / Forecast
1.02 / 0.93
Revenue / Forecast
308M / 309.74M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.92
Dividend Yield
1.56%
Industry Median 1.29%
Annualised payout
1.30
Paid annually
5-Years Growth
+5.39%
Growth Streak

Compare DIAS to Peers and Sector

Metrics to compare
DIAS
Peers
Sector
Relationship
P/E Ratio
28.3x26.9x−0.2x
PEG Ratio
-0.250.00
Price/Book
2.8x2.6x2.6x
Price / LTM Sales
3.4x2.5x2.7x
Upside (Analyst Target)
−3.6%19.2%66.0%
Fair Value Upside
Unlock7.8%10.8%Unlock

DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.

Employees
3242
Market
Italy

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.67M9.44%388.19M
Other Institutional Investors
28.70M57.99%2.39B
Public Companies & Retail Investors
16.12M32.58%1.34B
Total
49.5M100.00%4.11B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Investimenti e Partecipazioni Spa49.68%24,593,4542,043,716
M.c. S.r.l.4.65%2,300,000191,130

People Also Watch

11.555
AMPF
-1.79%
52.90
RECI
+0.09%
7.310
INWT
-0.81%
6.115
SFER
-4.38%
14.300
IVG
-0.56%

FAQ

What Is the Diasorin (Milan: DIAS) Share Price Today?

The Diasorin stock price today is 82.38 EUR.

What Stock Exchange Does Diasorin (DIAS) Trade On?

Diasorin is listed and trades on the Milan Stock Exchange.

What Is the Ticker (Stock Symbol) for Diasorin?

The stock symbol (also called a 'ticker') for Diasorin is "DIAS."

Does Diasorin Pay Dividends? What’s The Current DIAS Dividend Yield?

Yes, DIAS Pays Dividends to its Shareholders. The current Diasorin dividend yield is 1.6%%.

What Is the Current Diasorin Market Capitalisation?

As of today, Diasorin (Milan: DIAS) market cap is 4.08B EUR.

What Is Diasorin's (DIAS) Earnings Per Share (TTM)?

The Diasorin EPS is currently 2.92 (Trailing Twelve Months).

When Is the Next Diasorin Earnings Date?

Diasorin's next earnings report will be released on 12/03/2027.

Is DIAS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Diasorin moving averages and other technical indicators, the daily buy/sell signal for DIAS stock is Strong Buy.

How Many Times Has Diasorin Stock Split?

Diasorin has split 0 times. (See the DIAS stock split history page for full effective split date and price information.)

How Many Employees Does Diasorin Have?

Diasorin has 3242 employees, based on their latest Companies House report.

What is the current trading status of Diasorin (Milan: DIAS)?

As of 17/11/2026, Diasorin (DIAS) is trading at a share price of 82.38 EUR, with a previous close of 83.10 EUR. The stock has fluctuated within a day range of 82.34 EUR to 83.00 EUR, while its 52-week range spans from 52.34 EUR to 85.82 EUR.

What Is Diasorin (DIAS) Price Target According to Analysts?

The average 12-month price target for Diasorin is 79.63 EUR, with a high estimate of 105 EUR and a low estimate of 55 EUR. 6 analysts recommend buying the stock, while 5 suggest selling, leading to an overall rating of Neutral. The stock has an -3.34% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.